{"filing":{"accession_number":"0001104659-26-082341","cik":"0001477845","ticker":"ANVS","company_name":"Annovis Bio, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"tm2620172d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/tm2620172d1_8k.htm"},"events":[{"id":16931,"run_id":15156,"accession_number":"0001104659-26-082341","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Annovis announced full enrollment of its pivotal Phase 3 trial (NCT06709014) for buntanetap in early Alzheimer's disease, with 850 patients enrolled across 83 US clinical sites. This is a material operational milestone for a Phase 3 clinical-stage biotech company, as it represents a critical step toward potential regulatory approval and commercialization. The disclosure includes near-term data readout milestones (Q1 2027 symptomatic data, Q1 2028 disease-modifying data) and planned NDA submissions, which would directly impact the company's value and investor assessment.","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15187,"accession_number":"0001104659-26-082341","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Annovis announced full enrollment of its pivotal Phase 3 trial (NCT06709014) for buntanetap in early Alzheimer's disease, with 850 patients enrolled across 83 US clinical sites. This is a material operational milestone for a Phase 3 clinical-stage biotech company, as it represents a critical step toward potential regulatory approval and commercialization. The disclosure includes near-term data readout milestones (Q1 2027 symptomatic data, Q1 2028 disease-modifying data) and planned NDA submissions, which would directly impact the company's value and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:57:40.374570+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15187,"accession_number":"0001104659-26-082341","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Annovis announced full enrollment of its pivotal Phase 3 trial (NCT06709014) for buntanetap in early Alzheimer's disease, with 850 patients enrolled across 83 US clinical sites. This is a material operational milestone for a Phase 3 clinical-stage biotech company, as it represents a critical step toward potential regulatory approval and commercialization. The disclosure includes near-term data readout milestones (Q1 2027 symptomatic data, Q1 2028 disease-modifying data) and planned NDA submissions, which would directly impact the company's value and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:57:40.374570+00:00","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-07-09"}]}